MBX Biosciences, Inc. (NYSE:MBX) Director Purchases $8,000,000.00 in Stock

MBX Biosciences, Inc. (NYSE:MBX) Director Edward T. Mathers purchased 500,000 shares of the company’s stock in a transaction that occurred on Monday, September 16th. The shares were acquired at an average cost of $16.00 per share, with a total value of $8,000,000.00. Following the completion of the purchase, the director now owns 3,614,486 shares of the company’s stock, valued at $57,831,776. The acquisition was disclosed in a filing with the SEC, which is available at this link.

MBX Biosciences Stock Down 2.3 %

MBX opened at $21.00 on Thursday. MBX Biosciences, Inc. has a fifty-two week low of $20.51 and a fifty-two week high of $26.08.

MBX Biosciences Company Profile

MBX Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism.